A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)

Blockade of checkpoint receptors with monoclonal antibodies against CTLA-4, PD-1 and PD-L1 has shown great clinical success in several cancer subtypes, yielding unprecedented responses albeit a significant number of patients develop resistance and remain refractory. Both PD-1/PD-L1 and HER-2 signali...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Linlin, Overholser, Jay, Darby, Heather, Ede, Nicholas J., Kaumaya, Pravin T.P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542669/
https://www.ncbi.nlm.nih.gov/pubmed/36211807
http://dx.doi.org/10.1080/2162402X.2022.2127691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542669/
https://www.ncbi.nlm.nih.gov/pubmed/36211807
http://dx.doi.org/10.1080/2162402X.2022.2127691

Ejemplares similares